Celgene, Agios Drug Enasidenib Among New Filings At EMA
Executive Summary
Enasidenib, which last year became the first US-approved treatment for relapsed or refractory acute myeloid leukemia with an IDH2 mutation, is among a new crop of products being reviewed for marketing approval in the EU.
You may also be interested in...
Companies Keep The Faith As New Products Await EMA Verdict
Mitsubishi and Emmaus Life Sciences are among the companies that will find out this week whether the European Medicines Agency's drug evaluation committee, the CHMP, will recommend their new products for EU approval.
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.